Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: A novel therapeutic agent allowing noninvasive imaging and radioiodine therapy

H. V. Reddi, P. Madde, S. J. McDonough, M. A. Trujillo, J. C. Morris, R. M. Myers, Kah-Whye Peng, Stephen J Russell, B. McIver, N. L. Eberhardt

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression. To enhance prognosis of this fatal cancer, we validated the preclinical efficacy of measles virus (MV)-NIS, the vaccine strain of the oncolytic MV (MV-Edm), modified to include the NIS gene. Western blotting analysis confirmed that a panel of eight anaplastic thyroid cancer (ATC)-derived cell lines do not express NIS protein, but do express CD46, the MV receptor. In vitro cell death assays and in vivo xenograft studies demonstrate the oncolytic efficacy of MV-NIS in BHT-101 and KTC-3, ATC-derived cell lines. Radioactive iodine uptake along with single-photon emission computed tomography (SPECT)-computed tomography imaging of KTC-3 xenografts after 99Tcm administration confirmed NIS expression in vitro and in vivo, respectively, after virus treatment. Adjuvant administration of RAI, to MV-NIS-treated KTC-3 tumors showed a trend for increased tumor cell killing. As current treatment for ATC is only palliative, and MV-NIS is currently Food and Drug Administration approved for human clinical trials in myeloma, our data indicate that targeting ATC with MV-NIS could prove to be a novel therapeutic strategy for effective treatment of iodine-resistant ATC and will expedite its testing in clinical trials for this aggressive disease.

Original languageEnglish (US)
Pages (from-to)659-665
Number of pages7
JournalCancer Gene Therapy
Volume19
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Oncolytic Viruses
Measles virus
Iodine
Therapeutics
Heterografts
Clinical Trials
Virus Receptors
Cell Line
Neoplasms
Butylated Hydroxytoluene
Anaplastic Thyroid Carcinoma
sodium-iodide symporter
United States Food and Drug Administration
Cell Death
Vaccines
Western Blotting
Viruses

Keywords

  • anaplastic thyroid carcinoma
  • MV-NIS
  • novel therapeutic agent
  • sodium iodide symporter dysfunction

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer : A novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. / Reddi, H. V.; Madde, P.; McDonough, S. J.; Trujillo, M. A.; Morris, J. C.; Myers, R. M.; Peng, Kah-Whye; Russell, Stephen J; McIver, B.; Eberhardt, N. L.

In: Cancer Gene Therapy, Vol. 19, No. 9, 09.2012, p. 659-665.

Research output: Contribution to journalArticle

@article{daf6aa70a33e497d889d32aa99287545,
title = "Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: A novel therapeutic agent allowing noninvasive imaging and radioiodine therapy",
abstract = "Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression. To enhance prognosis of this fatal cancer, we validated the preclinical efficacy of measles virus (MV)-NIS, the vaccine strain of the oncolytic MV (MV-Edm), modified to include the NIS gene. Western blotting analysis confirmed that a panel of eight anaplastic thyroid cancer (ATC)-derived cell lines do not express NIS protein, but do express CD46, the MV receptor. In vitro cell death assays and in vivo xenograft studies demonstrate the oncolytic efficacy of MV-NIS in BHT-101 and KTC-3, ATC-derived cell lines. Radioactive iodine uptake along with single-photon emission computed tomography (SPECT)-computed tomography imaging of KTC-3 xenografts after 99Tcm administration confirmed NIS expression in vitro and in vivo, respectively, after virus treatment. Adjuvant administration of RAI, to MV-NIS-treated KTC-3 tumors showed a trend for increased tumor cell killing. As current treatment for ATC is only palliative, and MV-NIS is currently Food and Drug Administration approved for human clinical trials in myeloma, our data indicate that targeting ATC with MV-NIS could prove to be a novel therapeutic strategy for effective treatment of iodine-resistant ATC and will expedite its testing in clinical trials for this aggressive disease.",
keywords = "anaplastic thyroid carcinoma, MV-NIS, novel therapeutic agent, sodium iodide symporter dysfunction",
author = "Reddi, {H. V.} and P. Madde and McDonough, {S. J.} and Trujillo, {M. A.} and Morris, {J. C.} and Myers, {R. M.} and Kah-Whye Peng and Russell, {Stephen J} and B. McIver and Eberhardt, {N. L.}",
year = "2012",
month = "9",
doi = "10.1038/cgt.2012.47",
language = "English (US)",
volume = "19",
pages = "659--665",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer

T2 - A novel therapeutic agent allowing noninvasive imaging and radioiodine therapy

AU - Reddi, H. V.

AU - Madde, P.

AU - McDonough, S. J.

AU - Trujillo, M. A.

AU - Morris, J. C.

AU - Myers, R. M.

AU - Peng, Kah-Whye

AU - Russell, Stephen J

AU - McIver, B.

AU - Eberhardt, N. L.

PY - 2012/9

Y1 - 2012/9

N2 - Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression. To enhance prognosis of this fatal cancer, we validated the preclinical efficacy of measles virus (MV)-NIS, the vaccine strain of the oncolytic MV (MV-Edm), modified to include the NIS gene. Western blotting analysis confirmed that a panel of eight anaplastic thyroid cancer (ATC)-derived cell lines do not express NIS protein, but do express CD46, the MV receptor. In vitro cell death assays and in vivo xenograft studies demonstrate the oncolytic efficacy of MV-NIS in BHT-101 and KTC-3, ATC-derived cell lines. Radioactive iodine uptake along with single-photon emission computed tomography (SPECT)-computed tomography imaging of KTC-3 xenografts after 99Tcm administration confirmed NIS expression in vitro and in vivo, respectively, after virus treatment. Adjuvant administration of RAI, to MV-NIS-treated KTC-3 tumors showed a trend for increased tumor cell killing. As current treatment for ATC is only palliative, and MV-NIS is currently Food and Drug Administration approved for human clinical trials in myeloma, our data indicate that targeting ATC with MV-NIS could prove to be a novel therapeutic strategy for effective treatment of iodine-resistant ATC and will expedite its testing in clinical trials for this aggressive disease.

AB - Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression. To enhance prognosis of this fatal cancer, we validated the preclinical efficacy of measles virus (MV)-NIS, the vaccine strain of the oncolytic MV (MV-Edm), modified to include the NIS gene. Western blotting analysis confirmed that a panel of eight anaplastic thyroid cancer (ATC)-derived cell lines do not express NIS protein, but do express CD46, the MV receptor. In vitro cell death assays and in vivo xenograft studies demonstrate the oncolytic efficacy of MV-NIS in BHT-101 and KTC-3, ATC-derived cell lines. Radioactive iodine uptake along with single-photon emission computed tomography (SPECT)-computed tomography imaging of KTC-3 xenografts after 99Tcm administration confirmed NIS expression in vitro and in vivo, respectively, after virus treatment. Adjuvant administration of RAI, to MV-NIS-treated KTC-3 tumors showed a trend for increased tumor cell killing. As current treatment for ATC is only palliative, and MV-NIS is currently Food and Drug Administration approved for human clinical trials in myeloma, our data indicate that targeting ATC with MV-NIS could prove to be a novel therapeutic strategy for effective treatment of iodine-resistant ATC and will expedite its testing in clinical trials for this aggressive disease.

KW - anaplastic thyroid carcinoma

KW - MV-NIS

KW - novel therapeutic agent

KW - sodium iodide symporter dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84865266991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865266991&partnerID=8YFLogxK

U2 - 10.1038/cgt.2012.47

DO - 10.1038/cgt.2012.47

M3 - Article

C2 - 22790962

AN - SCOPUS:84865266991

VL - 19

SP - 659

EP - 665

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 9

ER -